A recently published report by Fact.MR reveals that the global antibacterial drugs market is projected to grow at a modest CAGR of 2.6% during the forecast period (2021-2031), expected to reach a value of US$ 62 Bn. In the short run, the market is poised to expand at a CAGR of 1.5% from 2020-2025 to reach US$ 50 Bn.

Historically, the market experienced sluggish growth, registering a 1% value CAGR from 2016 to 2020. At the end of the said historical period, the market was valued at around US$ 46 Bn. By 2021, it is likely to be valued at US$ 48 Bn. Prospects have dimmed majorly amidst the COVID-19 pandemic, with pharmaceutical companies shifting focus towards developing effective anti-viral vaccinations and drugs. This exercise is bound to consume a major part of their finances, relegating prospects for antibacterial drugs.

At the same time, factors such as an increase in the ageing population, growing demand for efficient and affordable antibacterial drugs, and an increasing number of multi-drug resistant bacterial strains are global antibacterial drugs market.

Get Sample Copy With Impact Analysis Of COVID-19 Of Market Report – https://www.factmr.com/connectus/sample?flag=Srep_id=4340           

Antibacterial Drugs Market- Scope of Report

A recent study by Fact.MR on the antibacterial drugs market offers a 10-year forecast for 2021 to 2031. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering antibacterial drugs.

The study also provides the dynamics responsible for influencing the future status of the antibacterial drugs market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the antibacterial drugs market, along with their product portfolios, enhances the reliability of this comprehensive research study.

Competitive Landscape

Competition in the global antibacterial drugs market is expected to rise, with players focusing on gaining a competitive advantage and increasing their market foothold. Various players around the world are investing in new RD projects, making joint ventures, and partnerships for being ahead in the competition among others.

• In September 2021, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.

• In July 2021, AstraZeneca announced that it has entered into a collaboration with Regeneron to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

Key Segments Covered

• Drug Class

  • β-lactam Antibacterial Drugs
  • Quinolone Antibacterial Drugs
  • Macrolide Antibacterial Drugs
  • Tetracycline Antibacterial Drugs
  • Aminoglycoside Antibacterial Drugs
  • Sulfonamide Antibacterial Drugs
  • Phenicols Antibacterial Drugs
  • Other Antibacterial Drugs

• Route of Administration

  • Enteral Antibacterial Drug Administration
  • Parenteral Antibacterial Drug Administration
  • Other Antibacterial Drug Administration Routes (Inhalation, Topical, etc.)

• Distribution Channel

  • Antibacterial Drug Sales via Hospital Pharmacies
  • Antibacterial Drug Sales via Drug Stores and Retail Pharmacies
  • Online Antibacterial Drug Sales 

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive industry 4.0 to healthcare retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: [email protected]
Visit Our Website: https://www.factmr.com